Treatment of Hidradenitis Suppurativa in Males
For male patients with hidradenitis suppurativa, treatment should follow a severity-based algorithm starting with topical therapies and systemic antibiotics for mild disease (Hurley I), escalating to combination antibiotics or biologics for moderate disease (Hurley II), and incorporating surgical intervention alongside medical therapy for severe disease (Hurley III). 1
Initial Assessment and Disease Staging
Evaluate disease severity using Hurley staging and the International Hidradenitis Suppurativa Severity Score System (IHS4) to guide treatment selection. 2 Screen for comorbidities including metabolic syndrome, inflammatory bowel disease, and mental health conditions at diagnosis, as these significantly impact treatment planning and outcomes. 1, 3
Treatment Algorithm by Disease Severity
Mild Disease (Hurley Stage I)
Start with topical therapies as first-line treatment:
Topical clindamycin 1% solution reduces pustules and improves patient self-assessment, though it has minimal effect on inflammatory nodules and abscesses. 1 Combine with benzoyl peroxide to reduce Staphylococcus aureus resistance development. 1
Antiseptic washes including chlorhexidine, benzoyl peroxide, or zinc pyrithione are recommended based on expert consensus, though no specific agent has proven superiority. 1
Resorcinol 15% cream (keratolytic and antiseptic) applied twice daily during flares and daily between flares reduces pain and abscess duration, though irritant dermatitis occurs frequently. 1
For acute flares:
- Intralesional triamcinolone 10 mg/mL (0.2-2.0 mL per lesion) significantly reduces erythema, edema, suppuration, and size within 1 day, with marked pain reduction. 1
Moderate Disease (Hurley Stage II)
Escalate to systemic antibiotics as primary therapy:
Clindamycin 300 mg twice daily plus rifampin 300 mg twice daily for 8-12 weeks is the most studied antibiotic combination, with response rates of 71-93% across multiple studies. 1 This combination can be repeated intermittently or used as adjuvant therapy with biologics.
Alternative triple therapy for refractory cases: moxifloxacin 400 mg once daily, metronidazole 500 mg three times daily (limited to 6 weeks to avoid neurologic toxicity), and rifampin 300 mg twice daily. 1 This achieves complete response in 100% of Hurley I, 80% of Hurley II, but only 17% of Hurley III patients. 1
Consider biologic therapy if antibiotics fail or for patients requiring long-term control:
- Adalimumab is the only FDA-approved biologic for HS and should be considered for moderate-to-severe disease unresponsive to antibiotics. 1, 2
Severe Disease (Hurley Stage III)
Combine medical and surgical approaches:
Biologics (adalimumab, or emerging options including IL-17 inhibitors like bimekizumab, IL-36 inhibitors like spesolimab, or JAK inhibitors like povorcitinib) as primary medical therapy. 2, 4
Surgical intervention is essential for severe disease, providing symptomatic relief, infection control, and reduced recurrence rates. 5 Surgical options range from tissue-sparing procedures to wide excision with reconstruction using skin grafts or flaps. 5
Antibiotics serve as adjunctive therapy to biologics or as bridge therapy to surgery, not as monotherapy. 1
Male-Specific Considerations
For penoscrotal involvement (affects 6% of male HS patients), surgical management is particularly important due to the anatomical challenges and functional implications. 5 Reconstruction techniques must be carefully selected for genital tissue, with skin grafts and flaps being preferred options. 5
Note: Unlike female patients, males do not benefit from hormonal therapies (oral contraceptives, spironolactone, finasteride) that target androgen pathways. 1 Treatment selection in males focuses exclusively on anti-inflammatory and antimicrobial approaches.
Emerging and Adjunctive Therapies
Fractional microneedling radiofrequency (FMR) shows 94% clinical improvement rates with 53% achieving ≥55% IHS4 reduction, particularly effective for facial, chest, and gluteal lesions. 6 This can be used as standalone therapy or combined with systemic treatments for refractory disease.
Zinc supplementation may be considered given evidence of lower serum zinc levels in HS patients, though direct evidence in HS is limited. 1
Treatment Stacking Approach
The most effective management employs treatment stacking: combining topical therapies, systemic antibiotics, biologics, surgical intervention, pain management, lifestyle modifications, and wound care simultaneously rather than sequentially. 2 This multimodal approach addresses the dynamic nature of HS and prevents delays that worsen prognosis. 7
Critical Pitfalls to Avoid
Do not delay aggressive medical therapy in moderate-to-severe disease—starting biologics or combination antibiotics early prevents sinus tract development and irreversible scarring. 7
Do not pursue medical therapy alone for too long in severe disease—surgical intervention should be incorporated when sinus tracts develop, not delayed indefinitely. 7
Do not use tetracycline or doxycycline monotherapy—these show minimal efficacy compared to combination regimens. 1
Do not use topical clindamycin without benzoyl peroxide due to resistance development. 1